Introduction
============

Hepatocellular carcinoma (HCC) is one of the most common human malignancies in China that partially attributes to the large hepatitis virus (hepatitis B virus or hepatitis C virus) carriers population.[@b1-ott-11-2945],[@b2-ott-11-2945] Because of the limitations of current clinical diagnosis options, most patients were found to have advanced HCC even at their initial diagnosis, which is no longer suitable for liver transplant or surgical operation.[@b3-ott-11-2945],[@b4-ott-11-2945] Advanced HCC patients could not be clinically benefited from systemic chemotherapies and molecular targeting therapies, for example, the first-line agent sorafenib and the second-line agent Regorafenib.[@b5-ott-11-2945],[@b6-ott-11-2945] About 30%--40% of patients are initially insensitive to sorafenib, whereas some patients with good initial responses become resistant to sorafenib as the therapy progressed.[@b7-ott-11-2945] Until now, the mechanism of sorafenib resistance remains unclear.

Triclosan (TCS, 5-chloro-2-(2,4-dichlorophenoxy) phenol) is an antimicrobial agent widely used in general consumer products for personal care and household cleaning.[@b8-ott-11-2945] Initially, TCS was considered as well tolerated and safe. However, TCS was recently found to affect endocrine and impair muscle contraction.[@b9-ott-11-2945] In 2014, Yueh et al reported that TCS could promote the progress of cirrhosis and HCC in mice model.[@b10-ott-11-2945] However, the exact role of TCS in HCC regulation or treatment is still largely unknown. In present work, TCS is showed to induce the expression of drug-resistance genes and promote the clearance of sorafenib in MHCC97-H cells. It is also found that TCS decreased the antitumor effect of sorafenib on subcutaneous and intrahepatic MHCC97-H tumor models. Based on the finding that TCS treatment induces sorafenib resistance in HCC model, this study may help to explain why exposure of TCS is detrimental for HCC patients.

Materials and methods
=====================

Cell culture and agents
-----------------------

MHCC97-H cells were purchased from Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China), a Chinese government organization containing typical biological samples, and cultured in DMEM (Thermo Fisher Scientific, Waltham, MA, USA) with 10% fetal bovine serum (Thermo Fisher Scientific) at 5% CO~2~, 37°C condition.[@b11-ott-11-2945],[@b12-ott-11-2945] Five lines of patient-derived HCC cell lines were a gift from Dr Fan Feng in Research Center for Clinical and Translational Medicine, The 302nd Hospital of Chinese PLA, Beijing, China. The collection of patient-derived HCC cell lines was with the approval for experiments from No 302nd hospital, Chinese PLA. Sorafenib (Cat No S7397) and TCS (Cat No S4541) were purchased from Selleck Corporation (Houston, TX, USA). TCS and sorafenib were dissolved separately in DMSO (Sigma Aldrich Co., St. Louis, MO, USA) and diluted by DMEM or other solution. Final concentration of DMSO in cell culture experiments was \<1‰.

Examination panel of drug resistance-related genes
--------------------------------------------------

Drug resistance-related genes' panel is mainly focused on drug metabolizing enzymes impacting drug efficacy and resistance ([Table 1](#t1-ott-11-2945){ref-type="table"}). Genes including 1) ATP-binding cassette transporters (ABCB1, ABCC1, ABCC2, ABCC3 or ABCG2); 2) cytochrome P450 (CYP; CYP1A2, CYP2B6, CYP2C11, CYP2C19, CYP2C22, CYP2C9, CYP2D6, CYP3A1, CYP3A4, CYP3A5, CYP4A11, CYP4B1); and 3) transferases (catechol-O-methyltransferase \[COMT\], dihydropyrimidine dehydrogenase \[DPYD\], thiopurine S-methyltransferase \[TPMT\], UDP glucuronosyltransferase family 1 member A1 \[UGT1A1\] or UDP glucuronosyltransferase family 2 member B7 \[UGT2B7\]); and 4) other drug resistance-related genes (5-hydroxytryptamine receptor 2A \[HTR2A\], apolipoprotein E \[Apo E\], aldehyde dehydrogenase 1 family \[ALDH1A1\], or adrenoceptor α2A \[ADRA2A\]), which would participate in drug resistance via mechanisms other than drug metabolism or clearance were chosen as control.

Total RNA isolation and quantitative polymerase chain reaction (qPCR)
---------------------------------------------------------------------

MHCC97-H cells were treated with indicated concentrations of TCS (0, 30, 100, 300, and 1,000 nmol/L) for 48 hours. Then, cells were harvested, and RNA extracting and qPCR experiments were performed following protocols described previously.[@b13-ott-11-2945],[@b14-ott-11-2945] The expression of drug resistance-related gene within MHCC97-H cells was examined by qPCR with primers listed in [Table 1](#t1-ott-11-2945){ref-type="table"}. The mRNA level of drug resistance-related genes from qPCR was analyzed by cluster analysis using SPSS software.

Growth inhibition assay of HCC cells
------------------------------------

MHCC97-H cells, which were pretreated with solvent control or 300 nmol/L TCS (the maximum-effect concentration for TCS to induce the expression of drug resistance-related genes without cell toxicity), were cultured with sorafenib for specified concentrations and time points. The concentration of sorafenib varies from 0.01 to 10 μmol/L, and the treating time points range from 0 to 72 hours. The viability of HCC cells was examined by MTT, and the absorbance was measured using a multifunctional microplate reader at 490 nm. Inhibition rates were calculated as: inhibition rate = (O.D. 490~control\ group~ − O.D. 490~administration\ group~)/(O.D. 490~control\ group~ − O.D. 490~blank~) × 100%.[@b15-ott-11-2945] Control group refers to cells treated with solvent control or at time 0-point, blank refers to the wells with no cells.

In vivo antitumor effects of sorafenib
--------------------------------------

All animal experiment protocols were approved by the Institutional Animal Care and Use Committee of the Beijing Institute of Pharmacology and Toxicology. All animal studies were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and associated guidelines.

For subcutaneous tumor model, nude mice (severe combined immune deficiency \[SCID\]) 4--6 weeks of age were provided by the animal center of Beijing Institute of Pharmacology and Toxicology. MHCC97-H cells were injected into mice right flank (5 × 10^6^ cells per inoculation point) as described previously.[@b16-ott-11-2945],[@b17-ott-11-2945] Tumor size was monitored every 3 days by measuring length and width with a caliper, the tumor volumes were calculated as length × width × width/2.[@b4-ott-11-2945] After 2--3 weeks' growth, when tumors reached 1,000--1,200 mm^3^ volume, mice were randomly divided into four groups and treated as follows: 1) mice were used as control group; 2) mice were injected intravenously with 500 μg/kg TCS (per day); 3) mice were administered 3 mg/kg oral sorafenib (per 2 days); and 4) mice were injected intravenously with 500 μg/kg TCS (per day) and administered 3 mg/kg oral sorafenib (per 2 days) treatment. After 3 weeks treatment, all mice were sacrificed and the final volume of tumors was measured. Every group contains 10 animals, and similar results were obtained from three repeats.

For intrahepatic model, MHCC97-H cells were directly inoculated into the right lobe of mice liver (1 × 10^5^ cells per animal).[@b20-ott-11-2945],[@b21-ott-11-2945] After 21 days,[@b20-ott-11-2945],[@b21-ott-11-2945] nude mice were randomly divided to four groups: 1) mice were used as control group; 2) mice were injected intravenously with 500 μg/kg TCS (per day); 3) mice were administered 3 mg/kg oral sorafenib (per 2 days); and 4) mice were injected intravenously with 500 μg/kg TCS (per day) and administered 3 mg/kg oral sorafenib (per 2 days) treatment. After 3 weeks treatment, all mice were injected intravenously with 400 μCi of ^18^F radiolabeled fluorodeoxyglucose (^18^F-FDG) and were examined by a positron emission tomography/computed tomography (PET/CT) scanner (Philips Corp., Holland, the Netherlands) as described by Xu et al.[@b21-ott-11-2945] An NaI (Tl) well counter (China Atom Corp., Beijing, China) was used to measure the radioactivity of organs (liver) to control (blood).[@b20-ott-11-2945],[@b21-ott-11-2945] Every group contains six animals, and similar results were obtained from three repeats.

Clearance of sorafenib
----------------------

To examine whether TCS could accelerate the metabolism or clearance of sorafenib in HCC cells, the clearance curve of sorafenib in HCC cells or tumors was determined. For cell-based experiments, MHCC97-H cells (1 × 10^8^--2 × 10^8^) were cultured with sorafenib at IC~50~ concentration (1 μmol/L) for 12 hours. Then, cells were divided into two groups and treated with solvent control or with 300 nmol/L concentration of TCS, separately. Cells were harvested at indicated time points and were lysed by sonication. Sorafenib in cells were extracted by acetonitrile (ACN) and quantitated using liquid chromatography/mass spectrometry-mass spectrometry (LC-MS/MS) as described in Allard et al,[@b18-ott-11-2945] He et al,[@b19-ott-11-2945] and Feng et al.[@b20-ott-11-2945]

For subcutaneous tumor experiments, MHCC97-H cells were injected into nude mice to form subcutaneous tumors as mentioned above. Sorafenib (2 mg) was dissolved in a mixture of DMSO (10 μL), PEG400 (50 μL), and Tween 80 (30 μL). Then, sorafenib solution was carefully and slowly added with ddH~2~O to 1 mL total volume accompanied with ultrasonic or churning treatment. The final concentration of sorafenib in this solution is 2 mg/mL. Sorafenib containing solution (Sor-Sol) was injected into HCC subcutaneous tumors (20 μL per tumor). At indicated time points, tumor tissues were harvested, and the sorafenib was extracted by ACN. The amount of sorafenib was measured by LC-MS/MS.[@b18-ott-11-2945]--[@b20-ott-11-2945]

Statistical analysis
--------------------

Statistical analysis was carried out using Bonferroni's correction with or without two-way analysis of variance in SPSS statistical software (IBM Corporation, Armonk, NY, USA). The IC~50~ value of sorafenib on MHCC97-H cells or half-life (t1/2 value) of sorafenib in MHCC97-H was calculated by Origin software (Version No 6.1, OriginLab Corporation, Northampton, MA, USA). A *P*-value \<0.05 was considered statistically significant.

Results
=======

Triclosan enhances the expression of drug resistance-related genes in MHCC97-H cells
------------------------------------------------------------------------------------

To figure out whether TCS promotes sorafenib resistance process, the expression of drug resistance-related genes in TCS-treated MHCC97-H cells, a representative aggressive HCC cell line, was measured by qPCR. As shown in [Figure 1](#f1-ott-11-2945){ref-type="fig"}, 30 and 100 nmol/L of TCS could increase the expression of some CYPs or ATP-binding cassettes (ABCs; Cluster 1), and 300 nmol/L of TCS was the maximal effective concentration. TCS did not affect the expression of non-drug metabolism-related genes, such as ALDH1A1, Apo E, ADRA2A, DPYD, COMT, TPMT, HTRA, or methylenetetrahydrofolate reductase (MTHFR; Cluster 2). Moreover, as a result from cluster analysis, [Figure 1](#f1-ott-11-2945){ref-type="fig"} indicated the relations among these genes. CYPs or ABCs are listed in the same cluster, and there is no difference between the effect of TCS on CYPs, UDP glucuronosyltransferase family (UGTs), or ABCs. ALDH1A1, Apo E, ADRA2A, DPYD, COMT, TPMT, HTRA, or MTHFR was located in another cluster. Results from cluster analysis indicated that TCS mainly induced the expression of genes related to drug metabolism or clearance, and would induce UGT, CYPs, or ABCs by similar mechanisms in MHCC97-H cells.

The cell viability after TCS treatment is shown in [Figure 2](#f2-ott-11-2945){ref-type="fig"} as TCS did not display cytotoxicity on MHCC97-H cells in tested concentration range. Interestingly, the higher concentrations of TCS would promote the proliferation of HCC cells. Therefore, TCS enhanced the drug resistance-related genes expression in MHCC97-H cells. For the following experiments, we chose the maximum-effect concentration (300 nmol/L) without cytotoxicity as a standard concentration for TCS treatment.

Triclosan promotes the clearance of sorafenib in MHCC97-H cells
---------------------------------------------------------------

MHCC97-H cells were treated with 1 μmol/L sorafenib for 12 hours before being washed and incubated in solvent control or 300 nmol/L TCS for another 12 hours. As shown in [Figure 3A](#f3-ott-11-2945){ref-type="fig"}, sorafenib was cleared within 24 hours in cultured MHCC97-H cells, and the half-life (t1/2 value) is 9.70 ± 0.42 hours. TCS treatment promoted the clearance of sorafenib in MHCC97-H cells as the half-life (t1/2 value) is reduced to 5.43 ± 0.28 hours.

Moreover, to test the effect of TCS on sorafenib clearance in vivo, MHCC97-H subcutaneous tumor-bearing mice were administrated with sorafenib solution formulation (Sor-Sol) and then treated with solvent control or 500 μg/kg TCS. Tumor tissues were harvested, and the remaining sorafenib in tumors was examined. As shown in [Figure 3B](#f3-ott-11-2945){ref-type="fig"}, sorafenib was completely cleared in tumor tissues at 48 hours with a half-life (t1/2 value) of 20.56 ± 0.57 hours. Treatment with 500 μg/kg TCS promoted the clearance of sorafenib in HCC tumors and decreased the half-life (t1/2 value) of sorafenib to 12.39 ± 0.77 hours.

Triclosan enhances sorafenib resistance in HCC
----------------------------------------------

The interaction of TCS and sorafenib in cell or cancer models was examined. As shown in [Figure 4](#f4-ott-11-2945){ref-type="fig"}, despite sorafenib inhibited MHCC97-H cells proliferation in in vitro model, treatment with 300 nmol/L TCS attenuates the antitumor effect of sorafenib, as the IC~50~ values of sorafenib on MHCC97-H cells elevated from 1.03 ± 0.07 to 9.64 ± 0.79 μmol/L. Next, to further confirm the effect of TCS on sorafenib's antitumor effect, patient-derived cell lines were used. As shown in [Figure 5](#f5-ott-11-2945){ref-type="fig"}, treatment with TCS significantly decreased the antitumor activity of sorafenib on patient-derived cell lines. The IC~50~ values of sorafenib were increased.

For in vivo subcutaneous tumors models, the tumor volumes and tumor weights of subcutaneous tumors were evaluated. As shown in [Figure 6](#f6-ott-11-2945){ref-type="fig"}, treatment with TCS promoted tumor growth, indicating that TCS may act as a tumor promoter, which is consistent with the previous studies.[@b10-ott-11-2945] Sorafenib, an antitumor drug, significantly inhibited tumor growth compared with control, as predicted. Sorafenib coupled with TCS showed less tumor suppressing effect compared with sorafenib alone, indicating that TCS reduced the antitumor effect of sorafenib.

Next, the intrahepatic MHCC97-H tumor model was established, and TCS, sorafenib, or combined treatments were performed. As shown in [Figure 7A](#f7-ott-11-2945){ref-type="fig"}, the intrahepatic growth of HCC cells in mice liver was identified by PET/CT screening. As expected, TCS enhanced the PET imaging in liver location compared with solvent control, whereas sorafenib treatment decreased the PET imaging in liver location of mice. TCS attenuated the antitumor effect of sorafenib on intrahepatic growth of HCC cells. The PET imaging was further confirmed by liver-to-blood radioactivation examination ([Figure 7A](#f7-ott-11-2945){ref-type="fig"}). Also, animals were sacrificed, and livers were collected to identify the nodules formed by HCC cells in liver organs. As shown in [Figure 7B](#f7-ott-11-2945){ref-type="fig"}, TCS promoted the growth of HCC cells in mice livers, and the nodules formed by HCC cells were larger than those in the control group. Sorafenib treatment significantly attenuated the intrahepatic growth of HCC cells in mice's liver, and the nodules formed by HCC cells were shrinking compared with those in the control group. TCS attenuated the antitumor effect of sorafenib on intrahepatic growth of HCC cells. Liver organ images were also supported by the PET imaging of separated liver organs ([Figure 7B](#f7-ott-11-2945){ref-type="fig"}). Taken together, both in vitro and in vivo data indicated that TCS enhanced the sorafenib resistance in HCC tumor models.

Discussion
==========

Although molecular targeting agent sorafenib was considered as a new hope for patients with advanced HCC, the overall prognosis and survival are still far from satisfaction.[@b21-ott-11-2945]--[@b23-ott-11-2945] Due to the genetic heterogeneity of HCC, some patients are intrinsically resistant to sorafenib, whereas for some other patients, acquired resistance to sorafenib often occur during treatment.[@b24-ott-11-2945] Zhu et al, systemically summarized the potential mechanisms of sorafenib resistance in their recent review.[@b7-ott-11-2945] However, the environmental inducer of sorafenib resistance remains practically unknown. In the present work, we showed that TCS induced the expression of several drug resistance-related genes in mice, promoted the clearance of sorafenib in both HCC cells and tumors, and enhanced the sorafenib resistance in MHCC97-H cells.

The exposure of environmental chemicals, for example, environmental poison or environmental endocrine-disrupting chemicals, remains a public health problem.[@b25-ott-11-2945] Certain chemicals can disrupt endocrine system and homeostasis.[@b25-ott-11-2945] TCS can be absorbed through human skin and oral mucosa and have been found persist in various human tissues and fluids.[@b26-ott-11-2945] Previously, TCS was considered as an endocrine disruptor, which promoted the progress of some endocrine-related human cancers, for example, breast cancer, similar to bisphenol A (BPA).[@b27-ott-11-2945]--[@b30-ott-11-2945] Yueh et al showed that TCS promotes the progress of cirrhosis and HCC in mice model.[@b10-ott-11-2945] However, the exact role of TCS in human HCC was unknown. This work reported the roles of TCS in inducing sorafenib resistance for the first time. Drug resistance-related gene clusters chosen in this work include CYP 450, ATP-binding cassette, and other transferases. These genes mediate the clearance of chemical drugs, indicating TCS may induce the expression of drug resistance-related genes to accelerate sorafenib clearance. Interestingly, our results also showed that TCS did not affect the expression of ALDH1A1, Apo E, ADRA2A, DPYD, COMT, TPMT, HTRA, or MTHFR, which all participate in drug resistance, but not by promoting drug metabolism or clearance.[@b31-ott-11-2945]--[@b40-ott-11-2945] These results confirmed the specificity of TCS function.

Moreover, nuclear receptors, for example, peroxisome proliferators-activated receptor (PPAR), pregnane X receptor (PXR), or constitutive androstane receptor (CAR), mediate the transcription of drug-resistance genes upon agonist activation.[@b40-ott-11-2945]--[@b46-ott-11-2945] Yueh et al indicated that TCS may be an agonist of PPAR, PXR, or CAR.[@b10-ott-11-2945] Therefore, it is valuable to reveal whether TCS interacts with nuclear receptors in the follow-up investigations.

Conclusion
==========

Our study revealed TCS promotes the clearance of sorafenib and induces sorafenib resistance in HCC cell line and in vivo tumor models, suggesting that exposure of TCS is extremely harmful for HCC patients undergoing sorafenib chemotherapy.
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![Triclosan induced the expression of drug-resistance genes in HCC cells.\
**Notes:** MHCC97-H cells were treated with solvent control, 30, 100, 300 nmol/L, or 1 μmol/L triclosan. Total RNA samples extracted from cell lines were analyzed by qPCR, and β-actin was chosen as a loading control. Results were analyzed by cluster analysis and shown as (**A**) relative mRNA level (mRNA amount compared to loading control) or (**B**) relative change of mRNA level (change folds of indicated group compared to solvent control group). Figures are shown as thermal map. The color changes refer the induction of gene expression. Lines in left part of each figures indicate the clusters.\
**Abbreviations:** ABCC1, ATP-binding cassette subfamily C member 1; ABCC2, ATP-binding cassette subfamily C member 2; ABCC3, ATP-binding cassette subfamily C member 3; ABCG2, ATP-binding cassette subfamily G member 2; ADRA2A, adrenoceptor α2A; ALDH1A1, aldehyde dehydrogenase 1 family; Apo E, apolipoprotein E; COMT, catechol-O-methyltransferase; CYP1A2, cytochrome P450 1A2; CYP2C11, cytochrome P450 2C11; CYP2C22, cytochrome P450 2C22; CYP3A1, cytochrome P450 3A1; CYP3A4, cytochrome P450 3A4; CYP3A5, cytochrome P450 3A5; CYP2C19, cytochrome P450 2C19; DPYD, dihydropyrimidine dehydrogenase; HCC, hepatocellular carcinoma; HTR2A, 5-hydroxytryptamine receptor 2A; MTHFR, methylenetetrahydrofolate reductase; qPCR, quantitative polymerase chain reaction; TPMT, thiopurine S-methyltransferase; UGT1A1, UDP glucuronosyltransferase family 1 member A1; UGT2B7, UDP glucuronosyltransferase family 2 member B7.](ott-11-2945Fig1){#f1-ott-11-2945}

![Triclosan did not have toxicity on MHCC97-H cells.\
**Notes:** MHCC97-H cells were treated with solvent control, 30, 100, 300 nmol/L, or 1 μmol/L triclosan for 48 hours before cells being analyzed by MTT experiments. Results are shown as relative cell number (mean ± SD). \**P*\<0.05 100 nmol/L group, 300 nmol/L group, or 1 μmol/L group versus solvent control group.](ott-11-2945Fig2){#f2-ott-11-2945}

![Triclosan promotes the metabolisms or clearances of sorafenib.\
**Notes:** (**A**) MHCC97-H cells, pretreated with 1 μmol/L sorafenib for 12 hours, were treated with solvent control or 300 nmol/L triclosan. Cells were harvested at indicated time points. (**B**) MHCC97-H cells were used to form subcutaneous tumor. Sorafenib solution (Sor-Sol) was injected into tumor tissues, and mice were then treated with solvent or 500 μg/kg triclosan. Tumor tissues were harvested at indicated time points. The cell samples or tumor tissue samples were analyzed by LC-MS/MS to value the sustaining of sorafenib concentration. The sustaining curve is shown as mean ± SD. \**P*\<0.05 solvent control group vs triclosan group.\
**Abbreviation:** LC-MS/MS, liquid chromatography/mass spectrometry-mass spectrometry.](ott-11-2945Fig3){#f3-ott-11-2945}

![Triclosan decreased the antitumor effect of sorafenib on in vitro MHCC97-H cell proliferation.\
**Notes:** MHCC97-H cells were treated with sorafenib with solvent control, or sorafenib with triclosan. Cells were treated with indicated concentration of drugs (**A**) or indicated time length (**B**). Then, cells were harvested for MTT experiments. The dose--effect curve, or time--effect curve, is shown as mean ± SD. \**P*\<0.05 solvent control group versus triclosan group.](ott-11-2945Fig4){#f4-ott-11-2945}

![Triclosan decreased the antitumor effect of sorafenib on in vitro patient-derived cells' proliferation.\
**Notes:** Five lines of patient-derived HCC cells were treated with sorafenib with solvent control, or sorafenib with triclosan. Cells were treated with indicated concentration of drugs or indicated time length. Then, cells were harvested for MTT experiments, and the IC~50~ values of sorafenib on cells were calculated. \**P*\<0.05 solvent control group versus triclosan group.\
**Abbreviation:** HCC, hepatocellular carcinoma.](ott-11-2945Fig5){#f5-ott-11-2945}

![Triclosan decreased the antitumor effect of sorafenib on MHCC97-H cell subcutaneous model.\
**Notes:** MHCC97-H cells were injected into nude mice to form subcutaneous tumors. Mice were divided into four treatment groups with indicated doses: 1) solvent control, 2) sorafenib, 3) triclosan, and 4) sorafenib + triclosan. Results are shown as (**A**) photographs, (**B**) tumor volumes, and (**C**) tumor weights. \**P*\<0.05 solvent control group versus triclosan group; solvent control group versus sorafenib group.](ott-11-2945Fig6){#f6-ott-11-2945}

![Triclosan decreased the antitumor effect of sorafenib on MHCC97-H cell intrahepatic model.\
**Notes:** MHCC97-H cells were injected into nude mice's liver lope to form intrahepatic tumors. Mice were divided into four groups: 1) solvent control, 2) sorafenib, 3) triclosan, and 4) sorafenib + triclosan. The tumor nodules formed by MHCC97-H cells in mice's liver were examined by PET/CT scanning. Results are shown as (**A**) PET/CT results from animals or radioactivation of liver to blood and (**B**) tumor organs or PET/CT results from liver organs. \**P*\<0.05 solvent control group versus triclosan group; solvent control group versus sorafenib group.\
**Abbreviation:** PET/CT, positron emission tomography/computed tomography.](ott-11-2945Fig7){#f7-ott-11-2945}

###### 

Primers used in quantitative polymerase chain reaction (qPCR) experiments

  mRNA                                                      Sequence
  --------------------------------------------------------- ----------------------------------
  ABCB1 (ATP-binding cassette subfamily B member 1)         
   Forward primer                                           5′-TCTGGACAAGCACTGAAAGATAAG-3′
   Reverse primer                                           5′-ACCTGCAAACTCTGAGCATACATA-3′
  ABCC1 (ATP-binding cassette subfamily C member 1)         
   Forward primer                                           5′-CCGTGTACTCCAACGCTGACAT-3′
   Reverse primer                                           5′-ATGCTGTGCGTGACCAAGATCC-3′
  ABCC2 (ATP-binding cassette subfamily C member 2)         
   Forward primer                                           5′-GCCAACTTGTGGCTGTGATAGG-3′
   Reverse primer                                           5′-ATCCAGGACTGCTGTGGGACAT-3′
  ABCC3 (ATP-binding cassette subfamily C member 3)         
   Forward primer                                           5′-GAGGAGAAAGCAGCCATTGGCA-3′
   Reverse primer                                           5′-TCCAATGGCAGCCGCACTTTGA-3′
  ABCG2 (ATP-binding cassette subfamily G member 2)         
   Forward primer                                           5′-GTTCTCAGCAGCTCTTCGGCTT-3′
   Reverse primer                                           5′-TCCTCCAGACACACCACGGATA-3′
  ADRA2A (adrenoceptor α2A)                                 
   Forward primer                                           5′-CCAGGGCACTCAGAAACC-3′
   Reverse primer                                           5′-AAACGACGACATAGAGGGACT-3′
  ALDH1A1 (aldehyde dehydrogenase 1 family)                 
   Forward primer                                           5′-ACAGGGTCTACTGAGGTTG-3′
   Reverse primer                                           5′-CTCCACGAAGATGCGAGA-3′
  Apo E (apolipoprotein E)                                  
   Forward primer                                           5′-GAATTCGCCCCGCCTGGTACAC-3′
   Reverse primer                                           5′-TAAGCTTGGCACGGCTGTCCAAGGA-3′
  COMT (catechol-O-methyltransferase)                       
   Forward primer                                           5′-TCCTTCTCAACTGCCATTCC-3′
   Reverse primer                                           5′-CCTTAGCGTTAGCGTCCGTC-3′
  CYP1A2 (cytochrome P450 1A2)                              
   Forward primer                                           5′-CATAGCCTCAGACCCCACAT-3′
   Reverse primer                                           5′-ACATTAGCCACCGATTCCAC-3′
  CYP2B6 (cytochrome P450 2B6)                              
   Forward primer                                           5′-TCTGGATGCCAATGGGGCACTGAA-3′
   Reverse primer                                           5′-GGGCGATGCCTTCACCAAGACAAATT-3′
  CYP2C11 (cytochrome P450 2C11)                            
   Forward primer                                           5′-GAGGACCATTGAGGACCGTA-3′
   Reverse primer                                           5′-GAGCACAGCCCAGGATAAAG-3′
  CYP2C19 (cytochrome P450 2C19)                            
   Forward primer                                           5′-AACTACTTCATGCCTTTCTC-3′
   Reverse primer                                           5′-GGTCCTTTGGGTCAATCAG-3′
  CYP2C22 (cytochrome P450 2C22)                            
   Forward primer                                           5′-ATGGGGATGGGAAAGAGAAC-3′
   Reverse primer                                           5′-TGCTGGAAAATGACACTGGA-3′
  CYP2C9 (cytochrome P450 2C9)                              
   Forward primer                                           5′-CTTGACACCACTCCAGTTGTC-3′
   Reverse primer                                           5′-AGATGGATAATGCCCCAGAG-3′
  CYP2D6 (cytochrome P450 2D6)                              
   Forward primer                                           5′-CTTCACCTCCCTGCTGCAG-3′
   Reverse primer                                           5′-TCACCAGGAAAGCAAAGACA-3′
  CYP3A1 (cytochrome P450 3A1)                              
   Forward primer                                           5′-AAATGCCTCTGTTTGCCATC-3′
   Reverse primer                                           5′-CTTTCCCCATAATCCCCACT-3′
  CYP3A4 (cytochrome P450 3A4)                              
   Forward primer                                           5′-CCCCTGAAATTAAGCTTAGGAG-3′
   Reverse primer                                           5′-TAATTTGAGGTCTCTGGTGTTCTCA-3′
  CYP3A5 (cytochrome P450 3A5)                              
   Forward primer                                           5′-CATGACTTAGTAGACAGATGAC-3′
   Reverse primer                                           5′-GGTCCAAACAGGGAAGAAATA-3′
  CYP4A11 (cytochrome P450 4A11)                            
   Forward primer                                           5′-CTTGGTCATGACTCCTAAACAGAGT-3′
   Reverse primer                                           5′-AGCCTGTTTACCAATTCTCTTTCAC-3′
  CYP4B1 (cytochrome P450 4B1)                              
   Forward primer                                           5′-GCCTCCTATCCCTGGACTCC-3′
   Reverse primer                                           5′-AGCCCCGAGGTGGCTCCTG-3′
  DPYD (dihydropyrimidine dehydrogenase)                    
   Forward primer                                           5′-TGTTCGGACAGAGCAAGATG-3′
   Reverse primer                                           5′-CTTCAATCCGGCCATTTCTA-3′
  HTR2A (5-hydroxytryptamine receptor 2A)                   
   Forward primer                                           5′-ATGTCCTCGGAGTGCTGTG-3′
   Reverse primer                                           5′-TAGCCACCCTGAGCCTATGT-3′
  MTHFR (methylenetetrahydrofolate reductase)               
   Forward primer                                           5′-GTGTCTGCGGGAGCCGATTTCAT-3′
   Reverse primer                                           5′-GGCGCTTCAGCACCTCTGTGG-3′
  TPMT (thiopurine S-methyltransferase)                     
   Forward primer                                           5′-AGGCAGCTAGGGAAAAAGAAAGCTG-3′
   Reverse primer                                           5′-CAAGCCTTATAGCCTTACACCCAGG-3′
  UGT1A1 (UDP glucuronosyltransferase family 1 member A1)   
   Forward primer                                           5′-GGCCCATCATGCCCAATAT-3′
   Reverse primer                                           5′-TTCAAATCCTGGGATAGTGGATT-3′
  UGT2B7 (UDP glucuronosyltransferase family 2 member B7)   
   Forward primer                                           5′-CAAAGGAHCTAAACACCTTCGG-3′
   Reverse primer                                           5′-CCGTAGTGTTTTCTTCATTGCC-3′
